nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-183-11-80-101nogr-1481Research ArticleОБЗОРREVIEWПараллели между неалкогольной жировой болезнью печени и неалкогольной жировой болезнью поджелудочной железы: в поисках точек соприкосновения или взгляд сквозь призму метаболического синдромаParallels between non-alcoholic fatty liver disease and non-alcoholic fatty pancreatic disease: looking for points of contact or regard through the lens of metabolic syndromehttps://orcid.org/0000-0003-3655-9554ГубергрицН. Б.GubergritsN. B.

Губергриц Наталья Борисовна, президент Украинского Клуба панкреатологов, профессор, д. м. н.

030039, г. Киев, ул. 40-летия Октября, 26

Natalia B. Gubergrits, President of the Ukrainian pancreatic Club, Professor, Dr. Sc. Med

030039, Kiev, 40th anniversary of October Street, 26

profnbg@ukr.netБеляеваН. В.ByelyayevaN. V.

Беляева Надежда Владимировна, консультант-гастроэнтеролог, кандидат медицинских наук

65114, г. Одесса, ул. Академика Королева, 17

Nadezhda V. Byelyayeva, Consultant Gastroenterologist, Cand. Of Med. Sci.

65114, Odessa, Academician Koroleva Street, 17

https://orcid.org/0000-0001-8239-6093МожинаТ. Л.MozhynaT. L.

Можина Татьяна Леонидовна, консультант, к. м. н.

61000, г. Харьков, ул. Целиноградская, 58Б

Tatiana L. Mozhyna, Consultant Doctor, Cand. Of Med. Sci.

61000, Kharkov, Tselnogradskaya Street, 58B

Украинский Клуб панкреатологовУкраинаUkrainian pancreatic ClubUkraineМедицинский центр «Медикап»УкраинаMedical Center “Medikap”UkraineЦентр здорового сердцаУкраинаHealthy Heart CenterUkraine2020141120201831180101Copyright © Губергриц Н.Б., Беляева Н.В., Можина Т.Л., 20202020Губергриц Н.Б., Беляева Н.В., Можина Т.Л.Gubergrits N.B., Byelyayeva N.V., Mozhyna T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1481Цель исследования

Цель исследования. Целью нашего исследования было проанализировать имеющиеся данные литературных источников, касающиеся вопросов этиологии, патогенеза, клиники, диагностики, а также особенностей лечения неалкогольной жировой болезни печени (НАЖБП) и неалкогольной жировой болезни поджелудочной железы (НАЖБПЖ).

Материалы и методы

Материалы и методы. Нами проведен ретроспективный анализ зарубежных источников литературы, содержащих актуальную современную информацию о состоянии проблемы НАЖБП и НАЖБПЖ.

Результаты

Результаты. НАЖБП и НАЖБПЖ развиваются на фоне метаболического синдрома (МС), системной инсулинорезистентности, окислительного стресса, изменения метаболизма липидов. Естественное течение НАЖБПЖ ассоциировано с высоким риском прогрессирования МС, возникновения НАЖБП, артериальной гипертонии, сахарного диабета 2-го типа, внешнесекреторной недостаточности поджелудочной железы (ПЖ), острого и хронического панкреатита, рака ПЖ. Коррекция компонентов МС позволяет уменьшить выраженность НАЖБП и НАЖБПЖ; проведение заместительной ферментной терапии способно улучшить функцию β-клеток при стеатозе ПЖ.

Заключение

Заключение. Возможности фармакологического лечения НАЖБП и НАЖБПЖ продолжают активно изучаться. Мы подчеркиваем целесообразность включения в схемы лечения НАЖБПЖ препаратов, содержащих ферменты ПЖ.

The aim

The aim. The aim of our study was to analyze the available data from literature sources concerning the issues of etiology, pathogenesis, clinic, diagnosis and features of treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty pancreatic disease (NAFPD).

Materials and methods

Materials and methods. We conducted a retrospective analysis of foreign literature sources that contain up-to-date information about the state of the problem of NAFLD and NAFPD.

Results

Results. NAFLD and NAFPD develop against the background of metabolic syndrome (MS), systemic insulin resistance, oxidative stress, changes in lipid metabolism. The natural course of NAFPD is associated with high risk of MS progression, occurrence of NAFLD, arterial hypertension, type 2 diabetes mellitus, exocrine pancreatic insufficiency, acute and chronic pancreatitis, pancreas cancer. Correction of the components of MS can reduce the severity of NAFLD and NAFPD; enzyme replacement therapy can improve the function of β-cells in pancreas steatosis.

Conclusion

Conclusion. The alternatives of the pharmacological treatment of NAFLD and NAFPD continue to be actively explored. We emphasize the need of including medications containing pancreatic enzymes in the treatment of NAFLD.

неалкогольная жировая болезнь печенинеалкогольная жировая болезнь поджелудочной железыметаболический синдромвнешнесекреторная недостаточность поджелудочной железыnon-alcoholic fatty liver diseasenon-alcoholic fatty pancreatic diseasemetabolic syndromecardiovascular diseasesexocrine pancreatic insufficiencyReferencesГубергриц Н. Б., Беляева Н. В., Лукашевич Г. М. и соавт. Доказательная панкреатология: что мы знаем о хроническом панкреатите к 2020 году?// Сучасна гастроентерологія, 2020, № 3, С. 96–110. https://doi.org/10.30978/MG-2020–3–96Gubergrits N. B., Belyaeva N. V., Lukashevich G. M. et al. Dokazatel`naya pankreatologiya: chto my` znaem o khronicheskom pankreatite k 2020 godu? [Evidence-based pancreatology: what do we know about chronic pancreatitis by 2020?]. Sovremennaya gastroe`nterologiya – Modern gastroenterology, 2020, no. 3, pp. 96–110. https://doi.org/10.30978/MG-2020–3–96.Стародубова А. В., Косюра С. Д., Ливанцова Е. Н. и соавт. Диагностика стеатоза поджелудочной железы у лиц с ожирением// Вестник клуба панкреатологов, 2019, № 4, С. 30–33.Starodubova A. V., Kosyura S. D., Livantsova E. N. et al. Diagnostika steatoza podzheludochnoj zhelezy` u licz s ozhireniem [Diagnosing pancreatic steatosis in obese patients]. Vestnik kluba pankreatologov – Bulletin of the Pancreatology Club, 2019, no. 4, pp. 30–33.Acharya C., Navina S., Singh V. P. Role of pancreatic fat in the outcomes of pancreatitis. Pancreatology, 2014, vol. 14, no. 5, pp. 403–408. doi:10.1016/j.pan.2014.06.004Acharya C., Navina S., Singh V. P. Role of pancreatic fat in the outcomes of pancreatitis. Pancreatology, 2014, vol. 14, no. 5, pp. 403–408. doi:10.1016/j.pan.2014.06.004Adams L.A., Anstee Q. M., Tilg H. et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017, no. 66, pp. 1138–53. doi:10.1136/gutjnl-2017–313884Adams L.A., Anstee Q. M., Tilg H. et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017, no. 66, pp. 1138–53. doi:10.1136/gutjnl-2017–313884Alempijevic T., Dragasevic S., Zec S. et al. Nonalcoholic fatty pancreas disease. Postgrad Med J, 2017, vol. 93, no. 1098, pp. 226–230. doi:10.1136/postgradmedj-2016–134546Alempijevic T., Dragasevic S., Zec S. et al. Nonalcoholic fatty pancreas disease. Postgrad Med J, 2017, vol. 93, no. 1098, pp. 226–230. doi:10.1136/postgradmedj-2016–134546Beger H.G., editors. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery, Oxford: Willey Blackwell, 2018, 1173 p.Beger H.G., editors. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery, Oxford: Willey Blackwell, 2018, 1173 p.Bi Y., Wang J. L., Li M. L. et al. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2019, vol. 35, no. 5, e3142. doi:10.1002/dmrr.3142Bi Y., Wang J. L., Li M. L. et al. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2019, vol. 35, no. 5, e3142. doi:10.1002/dmrr.3142Birkenfeld A.L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology, 2014, no. 59, pp. 713–23. doi:10.1002/hep.26672Birkenfeld A.L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology, 2014, no. 59, pp. 713–23. doi:10.1002/hep.26672Brown J.M., Hazen S. L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med, 2015, no. 66, pp. 343–59. doi:10.1146/annurev-med-060513–093205Brown J.M., Hazen S. L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med, 2015, no. 66, pp. 343–59. doi:10.1146/annurev-med-060513–093205Brunner K.T., Pedley A., Massaro J. M. et al. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int, 2020, vol. 40, no. 6, pp. 1339–1343. doi:10.1111/liv.14472.Brunner K.T., Pedley A., Massaro J. M. et al. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int, 2020, vol. 40, no. 6, pp. 1339–1343. doi:10.1111/liv.14472.Capurso G., Traini M., Piciucchi M. et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol, 2019, no. 12, pp. 129–139. doi:10.2147/CEG.S168266Capurso G., Traini M., Piciucchi M. et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol, 2019, no. 12, pp. 129–139. doi:10.2147/CEG.S168266Catanzaro R., Cuffari B., Italia A. et al. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J Gastroenterol, 2016, vol. 22, no. 34, pp. 7660–7675. doi:10.3748/wjg.v22.i34.7660Catanzaro R., Cuffari B., Italia A. et al. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J Gastroenterol, 2016, vol. 22, no. 34, pp. 7660–7675. doi:10.3748/wjg.v22.i34.7660Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, no. 67, pp. 328–57. doi:10.1002/hep.29367Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, no. 67, pp. 328–57. doi:10.1002/hep.29367Chiyanika C., Chan D. F., Hui S. C. et al. The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease. Pediatr Obes, 2020, e12653. doi:10.1111/ijpo.12653Chiyanika C., Chan D. F., Hui S. C. et al. The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease. Pediatr Obes, 2020, e12653. doi:10.1111/ijpo.12653Corey K.E., Misdraji J., Gelrud L. et al. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profi le. Lipids Health Dis, 2014, no. 13, p. 100. doi:10.1186/1476–511X-13–100Corey K.E., Misdraji J., Gelrud L. et al. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profi le. Lipids Health Dis, 2014, no. 13, p. 100. doi:10.1186/1476–511X-13–100Coulon S., Francque S., Colle I. et al. Evaluation of infl ammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine, 2012, no. 59, pp. 442–9. doi:10.1016/j.cyto.2012.05.001Coulon S., Francque S., Colle I. et al. Evaluation of infl ammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine, 2012, no. 59, pp. 442–9. doi:10.1016/j.cyto.2012.05.001Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology, 2012, no. 142, pp. 711–25.e6. doi:10.1053/j.gastro.2012.02.003Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology, 2012, no. 142, pp. 711–25.e6. doi:10.1053/j.gastro.2012.02.003DeFilippis A.P., Blaha M. J., Martin S. S. et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013, no. 227, pp. 429–36. doi:10.1016/j.atherosclerosis.2013.01.022DeFilippis A.P., Blaha M. J., Martin S. S. et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013, no. 227, pp. 429–36. doi:10.1016/j.atherosclerosis.2013.01.022Dite P., Blaho M., Bojkova M. et al. Nonalcoholic Fatty Pancreas Disease: Clinical Consequences. Dig Dis, 2020, vol. 38, no. 2, pp. 143–149. doi:10.1159/000505366Dite P., Blaho M., Bojkova M. et al. Nonalcoholic Fatty Pancreas Disease: Clinical Consequences. Dig Dis, 2020, vol. 38, no. 2, pp. 143–149. doi:10.1159/000505366Dominguez-Munoz J.E., Drewes A. M., Lindkvist B. et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis [published correction appears in Pancreatology. 2020 Jan;20(1):148]. Pancreatology, 2018, vol. 18, no. 8, pp. 847–854. doi:10.1016/j.pan.2018.09.016Dominguez-Munoz J.E., Drewes A. M., Lindkvist B. et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis [published correction appears in Pancreatology. 2020 Jan;20(1):148]. Pancreatology, 2018, vol. 18, no. 8, pp. 847–854. doi:10.1016/j.pan.2018.09.016El Hadi H., Di Vincenzo A., Vettor R. et al. Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells, 2020, vol. 9, no. 3, 567 p. doi:10.3390/cells9030567El Hadi H., Di Vincenzo A., Vettor R. et al. Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells, 2020, vol. 9, no. 3, 567 p. doi:10.3390/cells9030567Emre A., Terzi S., Celiker E. et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol, 2015, no. 116, pp. 1810–4. doi:10.1016/j.amjcard.2015.09.021Emre A., Terzi S., Celiker E. et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol, 2015, no. 116, pp. 1810–4. doi:10.1016/j.amjcard.2015.09.021European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, no. 64, pp. 1388–402. doi:10.1007/s00125–016–3902-yEuropean Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, no. 64, pp. 1388–402. doi:10.1007/s00125–016–3902-yFerrara D., Montecucco F., Dallegri F. et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol, 2019, vol. 234, no. 12, pp. 21630–21641. doi:10.1002/jcp.28821Ferrara D., Montecucco F., Dallegri F. et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol, 2019, vol. 234, no. 12, pp. 21630–21641. doi:10.1002/jcp.28821Francque S., Laleman W., Verbeke L. et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest, 2012, no. 92, pp. 1428–39. doi:10.1038/labinvest.2012.103Francque S., Laleman W., Verbeke L. et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest, 2012, no. 92, pp. 1428–39. doi:10.1038/labinvest.2012.103Francque S.M., van der Graaff D., Kwanten W. J. Nonalcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol, 2016, no. 65, pp. 425–43. doi:10.1016/j.jhep.2016.04.005Francque S.M., van der Graaff D., Kwanten W. J. Nonalcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol, 2016, no. 65, pp. 425–43. doi:10.1016/j.jhep.2016.04.005Fraser A., Harris R., Sattar N. et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care, 2009, no. 32, p. 741–50. doi:10.2337/dc08–1870Fraser A., Harris R., Sattar N. et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care, 2009, no. 32, p. 741–50. doi:10.2337/dc08–1870Fujii M., Ohno Y., Yamada M. et al. Impact of fatty pancreas and lifestyle on the development of subclinical chronic pancreatitis in healthy people undergoing a medical checkup. Environ Health Prev Med, 2019, vol. 24, no. 1, pp. 10–12. doi:10.1186/s12199–019–0763–2Fujii M., Ohno Y., Yamada M. et al. Impact of fatty pancreas and lifestyle on the development of subclinical chronic pancreatitis in healthy people undergoing a medical checkup. Environ Health Prev Med, 2019, vol. 24, no. 1, pp. 10–12. doi:10.1186/s12199–019–0763–2Gaborit B., Abdesselam I., Kober F. et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obes (Lond), 2015, vol. 39, no. 3, pp. 480–487. doi:10.1038/ijo.2014.126Gaborit B., Abdesselam I., Kober F. et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obes (Lond), 2015, vol. 39, no. 3, pp. 480–487. doi:10.1038/ijo.2014.126Gardner T.B., Adler D. G., Forsmark C. E. et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol, 2020, vol. 115, no. 3, pp. 322–339. doi:10.14309/ajg.0000000000000535Gardner T.B., Adler D. G., Forsmark C. E. et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol, 2020, vol. 115, no. 3, pp. 322–339. doi:10.14309/ajg.0000000000000535Gerst F., Wagner R., Oquendo M. B. et al. What role do fat cells play in pancreatic tissue? Mol Metab, 2019, no. 25, pp. 1–10. doi:10.1016/j.molmet.2019.05.001Gerst F., Wagner R., Oquendo M. B. et al. What role do fat cells play in pancreatic tissue? Mol Metab, 2019, no. 25, pp. 1–10. doi:10.1016/j.molmet.2019.05.001Gill R.M., Belt P., Wilson L. et al. Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol, 2011, no. 35, pp. 1400–4. doi:10.1097/PAS.0b013e3182254283Gill R.M., Belt P., Wilson L. et al. Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol, 2011, no. 35, pp. 1400–4. doi:10.1097/PAS.0b013e3182254283Guo K., Zhang L., Lu J. et al. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications, 2017, no. 31, pp. 80–5. doi:10.1016/j.jdiacomp.2016.09.008Guo K., Zhang L., Lu J. et al. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications, 2017, no. 31, pp. 80–5. doi:10.1016/j.jdiacomp.2016.09.008Hallsworth K., Hollingsworth K. G., Thoma C. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol, 2013, no. 58, pp. 757–62. doi:10.1016/j.jhep.2012.11.015Hallsworth K., Hollingsworth K. G., Thoma C. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol, 2013, no. 58, pp. 757–62. doi:10.1016/j.jhep.2012.11.015Heiskanen M.A., Motiani K. K., Mari A. et al. Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial. Diabetologia, 2018, vol. 61, no. 8, pp. 1817–1828. doi:10.1007/s00125–018–4627-xHeiskanen M.A., Motiani K. K., Mari A. et al. Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial. Diabetologia, 2018, vol. 61, no. 8, pp. 1817–1828. doi:10.1007/s00125–018–4627-xHonka H., Koffert J., Hannukainen J. et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab, 2015, vol. 100, no. 5, pp. 2015–2023. doi:10.1210/jc.2014–4236Honka H., Koffert J., Hannukainen J. et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab, 2015, vol. 100, no. 5, pp. 2015–2023. doi:10.1210/jc.2014–4236Huang C.T., Lin C. K., Lee T. et al. Pancreatic Fibrosis and Chronic Pancreatitis: Mini-Review of Non-Histologic Diagnosis for Clinical Applications. Diagnostics (Basel), 2020, vol. 10, no. 2, E87. doi:10.3390/diagnostics10020087Huang C.T., Lin C. K., Lee T. et al. Pancreatic Fibrosis and Chronic Pancreatitis: Mini-Review of Non-Histologic Diagnosis for Clinical Applications. Diagnostics (Basel), 2020, vol. 10, no. 2, E87. doi:10.3390/diagnostics10020087Jaruvongvanich V., Wirunsawanya K., Sanguankeo A. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis, 2016, no. 48, pp. 1410–7. doi:10.1016/j.dld.2016.09.002Jaruvongvanich V., Wirunsawanya K., Sanguankeo A. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis, 2016, no. 48, pp. 1410–7. doi:10.1016/j.dld.2016.09.002Kang J.H., Cho K. I., Kim S. et al. Relationship between nonalcoholic fatty liver disease and carotid artery atherosclerosis beyond metabolic disorders in non-diabetic patients. J Cardiovasc Ultrasound, 2012, no. 20, pp. 126–33. doi:10.4250/jcu.2012.20.3.126Kang J.H., Cho K. I., Kim S. et al. Relationship between nonalcoholic fatty liver disease and carotid artery atherosclerosis beyond metabolic disorders in non-diabetic patients. J Cardiovasc Ultrasound, 2012, no. 20, pp. 126–33. doi:10.4250/jcu.2012.20.3.126Kasumov T., Edmison J. M., Dasarathy S. et al. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism, 2011, no. 60, pp. 776–81. doi:10.1016/j.metabol.2010.07.027Kasumov T., Edmison J. M., Dasarathy S. et al. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism, 2011, no. 60, pp. 776–81. doi:10.1016/j.metabol.2010.07.027Keskin M., Hayiroglu M. I., Uzun A. O. et al. Effect of nonalcoholic fatty liver disease on in-hospital and longterm outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol, 2017, no. 120, pp. 1720–6. doi:10.1016/j.amjcard.2017.07.107Keskin M., Hayiroglu M. I., Uzun A. O. et al. Effect of nonalcoholic fatty liver disease on in-hospital and longterm outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol, 2017, no. 120, pp. 1720–6. doi:10.1016/j.amjcard.2017.07.107Ketwaroo G.A., Graham D. Y. Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain. Adv Exp Med Biol, 2019, no. 1148, pp. 323–343. doi:10.1007/978–981–13–7709–9_14Ketwaroo G.A., Graham D. Y. Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain. Adv Exp Med Biol, 2019, no. 1148, pp. 323–343. doi:10.1007/978–981–13–7709–9_14Kim J., Lee D. Y., Park S. et al. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic infl ammation. PLoS One, 2017, no. 12, e0180118. doi:10.1371/journal.pone.0180118Kim J., Lee D. Y., Park S. et al. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic infl ammation. PLoS One, 2017, no. 12, e0180118. doi:10.1371/journal.pone.0180118Kumar R., Priyadarshi R. N., Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol, 2020, vol. 8, no. 1, pp. 76–86. doi:10.14218/JCTH.2019.00051Kumar R., Priyadarshi R. N., Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol, 2020, vol. 8, no. 1, pp. 76–86. doi:10.14218/JCTH.2019.00051Lazar M.V., Eapen M., Nair H. R. et al. Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity. Indian J Gastroenterol, 2020, vol. 39, no. 1, pp. 42–49. doi:10.1007/s12664–020–01024-z.Lazar M.V., Eapen M., Nair H. R. et al. Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity. Indian J Gastroenterol, 2020, vol. 39, no. 1, pp. 42–49. doi:10.1007/s12664–020–01024-z.Leamy A.K., Egnatchik R. A., Young J. D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res, 2013, no. 52, pp. 165–74. doi:10.1016/j.plipres.2012.10.004Leamy A.K., Egnatchik R. A., Young J. D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res, 2013, no. 52, pp. 165–74. doi:10.1016/j.plipres.2012.10.004Lesmana C.R., Pakasi L. S., Inggriani S. et al. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol, 2015, no. 15, pp. 174–7. doi:10.1186/s12876–015–0404–1Lesmana C.R., Pakasi L. S., Inggriani S. et al. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol, 2015, no. 15, pp. 174–7. doi:10.1186/s12876–015–0404–1Lesmana C., Gani R. A., Lesmana L. A. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience. JGH Open, 2017, vol. 2, no. 1, pp. 4–7. doi:10.1002/jgh3.12032Lesmana C., Gani R. A., Lesmana L. A. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience. JGH Open, 2017, vol. 2, no. 1, pp. 4–7. doi:10.1002/jgh3.12032Ma J., Hwang S. J., Pedley A. et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol, 2017, no. 66, pp. 390–7. doi:10.1016/j.jhep.2016.09.022Ma J., Hwang S. J., Pedley A. et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol, 2017, no. 66, pp. 390–7. doi:10.1016/j.jhep.2016.09.022Mahfood Haddad T., Hamdeh S., Kanmanthareddy A. et al. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr, 2017, vol. 11, no. 1, S209–16. doi:10.1016/j.dsx.2016.12.033Mahfood Haddad T., Hamdeh S., Kanmanthareddy A. et al. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr, 2017, vol. 11, no. 1, S209–16. doi:10.1016/j.dsx.2016.12.033Majumder S., Philip N. A., Takahashi N. et al. Fatty Pancreas: Should We Be Concerned? Pancreas, 2017, vol. 46, no. 10), pp. 1251–1258. doi:10.1097/MPA.0000000000000941Majumder S., Philip N. A., Takahashi N. et al. Fatty Pancreas: Should We Be Concerned? Pancreas, 2017, vol. 46, no. 10), pp. 1251–1258. doi:10.1097/MPA.0000000000000941Mandai K., Uno K., Nakase K. et al. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms. J Med Ultrason, 2019, vol. 46, no. 4, pp. 435–439. doi:10.1007/s10396–019–00949-zMandai K., Uno K., Nakase K. et al. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms. J Med Ultrason, 2019, vol. 46, no. 4, pp. 435–439. doi:10.1007/s10396–019–00949-zMannisto V.T., Simonen M., Soininen P. et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res, 2014, no. 55, pp. 2676–84. doi:10.1194/jlr.P054387Mannisto V.T., Simonen M., Soininen P. et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res, 2014, no. 55, pp. 2676–84. doi:10.1194/jlr.P054387Mantovani A., Byrne C. D., Bonora E. et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care, 2018, no. 41, pp. 372–82. doi:10.2337/dc17–1902Mantovani A., Byrne C. D., Bonora E. et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care, 2018, no. 41, pp. 372–82. doi:10.2337/dc17–1902Milovanovic T., Dragasevic S., Stojkovic Lalosevic M. et al. Ultrasonographic Evaluation of Fatty Pancreas in Serbian Patients with Non Alcoholic Fatty Liver Disease-A Cross Sectional Study. Medicina (Kaunas), 2019, vol. 55, no. 10, pp. 697–8. doi:10.3390/medicina55100697Milovanovic T., Dragasevic S., Stojkovic Lalosevic M. et al. Ultrasonographic Evaluation of Fatty Pancreas in Serbian Patients with Non Alcoholic Fatty Liver Disease-A Cross Sectional Study. Medicina (Kaunas), 2019, vol. 55, no. 10, pp. 697–8. doi:10.3390/medicina55100697Nghiem D.D., Olson P. R., Ormond D. The “fatty pancreas allograft”: anatomo-pathologic fi ndings and clinical experience. Transplant Proc, 2004, vol. 36, no. 4, pp. 1045–1047. doi:10.1016/j.transproceed.2004.04.032Nghiem D.D., Olson P. R., Ormond D. The “fatty pancreas allograft”: anatomo-pathologic fi ndings and clinical experience. Transplant Proc, 2004, vol. 36, no. 4, pp. 1045–1047. doi:10.1016/j.transproceed.2004.04.032Niederseer D., Wernly S., Bachmayer S. et al. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. J Clin Med, 2020, vol. 9, no. 4, pp. 1065–6. doi:10.3390/jcm9041065Niederseer D., Wernly S., Bachmayer S. et al. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. J Clin Med, 2020, vol. 9, no. 4, pp. 1065–6. doi:10.3390/jcm9041065Pacana T., Cazanave S., Verdianelli A. et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One, 2015, vol. 10, no. 8, e0136822. doi:10.1371/journal.pone.0136822.Pacana T., Cazanave S., Verdianelli A. et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One, 2015, vol. 10, no. 8, e0136822. doi:10.1371/journal.pone.0136822.Pickhardt P.J., Hahn L., Munoz del Rio A. et al. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. Am J Roentgenology, 2014, no. 202, pp. 752–8. doi:10.2214/AJR.13.11367Pickhardt P.J., Hahn L., Munoz del Rio A. et al. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. Am J Roentgenology, 2014, no. 202, pp. 752–8. doi:10.2214/AJR.13.11367Pinnick K.E., Collins S. C.., Londos C et al. Pancreatic ectopic fat is characterized by adipocyte infi ltration and altered lipid composition. Obesity (Silver Spring), 2008, vol. 16, no. 3, pp. 522–530. doi:10.1038/oby.2007.110Pinnick K.E., Collins S. C.., Londos C et al. Pancreatic ectopic fat is characterized by adipocyte infi ltration and altered lipid composition. Obesity (Silver Spring), 2008, vol. 16, no. 3, pp. 522–530. doi:10.1038/oby.2007.110Pinte L., Balaban D. V., Băicuş C. et al. Non-alcoholic fatty pancreas disease – practices for clinicians. Rom J Intern Med, 2019, vol. 57, no. 3, pp. 209–219. doi:10.2478/rjim-2019–0005Pinte L., Balaban D. V., Băicuş C. et al. Non-alcoholic fatty pancreas disease – practices for clinicians. Rom J Intern Med, 2019, vol. 57, no. 3, pp. 209–219. doi:10.2478/rjim-2019–0005Pisto P., Santaniemi M., Bloigu R. et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 2014, vol. 4, no. 3, e004973. doi:10.1136/bmjopen-2014–004973Pisto P., Santaniemi M., Bloigu R. et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 2014, vol. 4, no. 3, e004973. doi:10.1136/bmjopen-2014–004973Prachayakul V., Aswakul. P. Pancreatic Steatosis: What Should Gastroenterologists Know? JOP, 2015, vol 16, no. 3, pp. 227–231.Prachayakul V., Aswakul. P. Pancreatic Steatosis: What Should Gastroenterologists Know? JOP, 2015, vol 16, no. 3, pp. 227–231.Puchner SB, Lu MT, Mayrhofer T, et al. Highrisk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology, 2015, no. 274, pp. 693–701. doi:10.1148/radiol.14140933Puchner SB, Lu MT, Mayrhofer T, et al. Highrisk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology, 2015, no. 274, pp. 693–701. doi:10.1148/radiol.14140933Puri P., Sanyal A. J. Nonalcoholic fatty liver disease: Defi nitions, risk factors, and workup. Clin Liver Dis (Hoboken), 2012, vol. 1, no. 4, pp. 99‐103. doi:10.1002/cld.81Puri P., Sanyal A. J. Nonalcoholic fatty liver disease: Defi nitions, risk factors, and workup. Clin Liver Dis (Hoboken), 2012, vol. 1, no. 4, pp. 99‐103. doi:10.1002/cld.81Ramkissoon R., Gardner T. B. Pancreatic Steatosis: An Emerging Clinical Entity. Am J Gastroenterol, 2019, vol. 114, no. 11, pp. 1726–1734. doi:10.14309/ajg.0000000000000262Ramkissoon R., Gardner T. B. Pancreatic Steatosis: An Emerging Clinical Entity. Am J Gastroenterol, 2019, vol. 114, no. 11, pp. 1726–1734. doi:10.14309/ajg.0000000000000262Romana B.S., Chela H., Dailey F. et al. Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review. Endocr Metab Immune Disord Drug Targets, 2018, vol. 18, no. 6, pp. 547–554. doi:10.2174/1871530318666180328111302Romana B.S., Chela H., Dailey F. et al. Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review. Endocr Metab Immune Disord Drug Targets, 2018, vol. 18, no. 6, pp. 547–554. doi:10.2174/1871530318666180328111302Sabag A., Way K. L., Keating S. et al. Exercise and ectopic fat in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab, 2017, vol. 43, no. 3, pp. 195–210. doi:10.1016/j.diabet.2016.12.006Sabag A., Way K. L., Keating S. et al. Exercise and ectopic fat in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab, 2017, vol. 43, no. 3, pp. 195–210. doi:10.1016/j.diabet.2016.12.006Sakai N.S., Taylor S. A., Chouhan M. D. Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat. Br J Radiol, 2018, vol. 91, no. 1089, pp. 2018–67. doi:10.1259/bjr.20180267Sakai N.S., Taylor S. A., Chouhan M. D. Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat. Br J Radiol, 2018, vol. 91, no. 1089, pp. 2018–67. doi:10.1259/bjr.20180267Shah N., Rocha J.P, Bhutiani N. et al. Nonalcoholic Fatty Pancreas Disease. Nutr Clin Pract, 2019, vol. 34, no. 1, pp. S49–S56. doi:10.1002/ncp.10397Shah N., Rocha J.P, Bhutiani N. et al. Nonalcoholic Fatty Pancreas Disease. Nutr Clin Pract, 2019, vol. 34, no. 1, pp. S49–S56. doi:10.1002/ncp.10397Shobassy M., Husainat N., Tabash A. et al. Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterol Res Pract, 2019, no. 2019, pp. 5290642. doi:10.1155/2019/5290642Shobassy M., Husainat N., Tabash A. et al. Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterol Res Pract, 2019, no. 2019, pp. 5290642. doi:10.1155/2019/5290642Siddiqui M.S., Fuchs M., Idowu M. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profi le. Clin Gastroenterol Hepatol, 2015, no. 13, pp. 1000–8.e3. doi:10.1016/j.cgh.2014.10.008Siddiqui M.S., Fuchs M., Idowu M. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profi le. Clin Gastroenterol Hepatol, 2015, no. 13, pp. 1000–8.e3. doi:10.1016/j.cgh.2014.10.008Singh R.G., Yoon H. D., Poppitt S. et al. Ectopic fat accumulation in the pancreas and its biomarkers: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2017, vol. 33, no. 8, pp. 10–11.1002/dmrr.2918. doi:10.1002/dmrr.2918Singh R.G., Yoon H. D., Poppitt S. et al. Ectopic fat accumulation in the pancreas and its biomarkers: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2017, vol. 33, no. 8, pp. 10–11.1002/dmrr.2918. doi:10.1002/dmrr.2918Singh R.G., Yoon H. D., Wu L. et al. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism, 2017, no. 69, pp. 1–13. doi:10.1016/j.metabol.2016.12.012Singh R.G., Yoon H. D., Wu L. et al. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism, 2017, no. 69, pp. 1–13. doi:10.1016/j.metabol.2016.12.012Sinn D.H., Kang D., Chang Y. et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 2017, no. 66, pp. 323–9. doi:10.1136/gutjnl-2016–311854Sinn D.H., Kang D., Chang Y. et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 2017, no. 66, pp. 323–9. doi:10.1136/gutjnl-2016–311854Skurk T., Alberti-Huber C., Herder C. et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab, 2007, vol. 92, no. 3, pp. 1023–1033. doi:10.1210/jc.2006–1055Skurk T., Alberti-Huber C., Herder C. et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab, 2007, vol. 92, no. 3, pp. 1023–1033. doi:10.1210/jc.2006–1055Smereczyński A., Kołaczyk K. Is a fatty pancreas a banal lesion? J Ultrason, 2016, vol. 16, no. 66, pp. 273–280. doi:10.15557/JoU.2016.0027Smereczyński A., Kołaczyk K. Is a fatty pancreas a banal lesion? J Ultrason, 2016, vol. 16, no. 66, pp. 273–280. doi:10.15557/JoU.2016.0027Smits M.M., van Geenen E. The clinical significance of pancreatic steatosis. Nat. Rev. Gastroenterol. Hepatol., 2011, no. 8, pp. 169–77. doi:10.1038/nrgastro.2011.4Smits M.M., van Geenen E. The clinical significance of pancreatic steatosis. Nat. Rev. Gastroenterol. Hepatol., 2011, no. 8, pp. 169–77. doi:10.1038/nrgastro.2011.4Sonmez A., Nikolic D., Dogru T. et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol, 2015, no. 9, pp. 576–82. doi:10.1016/j.jacl.2015.03.010Sonmez A., Nikolic D., Dogru T. et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol, 2015, no. 9, pp. 576–82. doi:10.1016/j.jacl.2015.03.010Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol, 2008, no. 49, pp. 600–7. doi:10.1016/j.jhep.2008.06.012Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol, 2008, no. 49, pp. 600–7. doi:10.1016/j.jhep.2008.06.012Souza-Mello V., Gregório B. M., Cardoso-de-Lemos F. et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond), 2010, vol. 119, no. 6, pp. 239–250. doi:10.1042/CS20100061Souza-Mello V., Gregório B. M., Cardoso-de-Lemos F. et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond), 2010, vol. 119, no. 6, pp. 239–250. doi:10.1042/CS20100061Sperling L.S., Mechanick J. I., Neeland I. et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol, 2015, no. 66, pp. 1050–67. doi:10.1016/j.jacc.2015.06.1328Sperling L.S., Mechanick J. I., Neeland I. et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol, 2015, no. 66, pp. 1050–67. doi:10.1016/j.jacc.2015.06.1328Sreedhar U.L., DeSouza S.V., Park B. et al. A Systematic Review of Intra-pancreatic Fat Deposition and Pancreatic Carcinogenesis. J Gastrointest Surg, 2019, 10.1007/s11605–019–04417–4. doi:10.1007/s11605–019–04417–4Sreedhar U.L., DeSouza S.V., Park B. et al. A Systematic Review of Intra-pancreatic Fat Deposition and Pancreatic Carcinogenesis. J Gastrointest Surg, 2019, 10.1007/s11605–019–04417–4. doi:10.1007/s11605–019–04417–4Stahl E.P., Dhindsa D. S., Lee S. et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019, vol. 73, no. 8, pp. 948–963. doi:10.1016/j.jacc.2018.11.050Stahl E.P., Dhindsa D. S., Lee S. et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019, vol. 73, no. 8, pp. 948–963. doi:10.1016/j.jacc.2018.11.050Sujishi T., Fukunishi S., Ii M. et al. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. J Clin Biochem Nutr, 2015, vol. 57, no. 3, pp. 244–253. doi:10.3164/jcbn.15–84Sujishi T., Fukunishi S., Ii M. et al. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. J Clin Biochem Nutr, 2015, vol. 57, no. 3, pp. 244–253. doi:10.3164/jcbn.15–84Tahtac M., Algın O., Karakan T. et al. Can pancreatic steatosis affect exocrine functions of pancreas? Turk J Gastroenterol, 2018, vol. 29, no. 5, pp. 588–594. doi:10.5152/tjg.2018.17696Tahtac M., Algın O., Karakan T. et al. Can pancreatic steatosis affect exocrine functions of pancreas? Turk J Gastroenterol, 2018, vol. 29, no. 5, pp. 588–594. doi:10.5152/tjg.2018.17696Targher G., Byrne C. D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol, 2016, no. 65, pp. 589–600. doi:10.1016/j.jhep.2016.05.013Targher G., Byrne C. D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol, 2016, no. 65, pp. 589–600. doi:10.1016/j.jhep.2016.05.013Tirkes T., Jeon C..Y, Li L. et al. Association of Pancreatic Steatosis With Chronic Pancreatitis, Obesity, and Type 2 Diabetes Mellitus. Pancreas, 2019, vol. 48, no. 3, pp. 420–426. doi:10.1097/MPA.0000000000001252Tirkes T., Jeon C..Y, Li L. et al. Association of Pancreatic Steatosis With Chronic Pancreatitis, Obesity, and Type 2 Diabetes Mellitus. Pancreas, 2019, vol. 48, no. 3, pp. 420–426. doi:10.1097/MPA.0000000000001252Tomita Y., Azuma K., Nonaka Y. et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas, 2014, vol. 43, no. 7, pp. 1032–1041. doi: 10.1097/MPA.0000000000000159.Tomita Y., Azuma K., Nonaka Y. et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas, 2014, vol. 43, no. 7, pp. 1032–1041. doi: 10.1097/MPA.0000000000000159.Treeprasertsuk S., Leverage S., Adams L. et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int, 2012, no. 32, pp. 945–50. doi:10.1002/hep4.1391Treeprasertsuk S., Leverage S., Adams L. et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int, 2012, no. 32, pp. 945–50. doi:10.1002/hep4.1391Tripodi A., Fracanzani A. L., Primignani M. et al. Procoagulant imbalance in patients with nonalcoholic fatty liver disease. J Hepatol, 2014, no. 61, pp. 148–54. doi:10.1016/j.jhep.2016.09.025Tripodi A., Fracanzani A. L., Primignani M. et al. Procoagulant imbalance in patients with nonalcoholic fatty liver disease. J Hepatol, 2014, no. 61, pp. 148–54. doi:10.1016/j.jhep.2016.09.025Tsatsoulis A., Mantzaris M. D., Bellou S. et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment – an evolutionary perspective. Metabolism, 2013, vol 62, no. 5, pp. 622–633. doi:10.1016/j.metabol.2012.11.004Tsatsoulis A., Mantzaris M. D., Bellou S. et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment – an evolutionary perspective. Metabolism, 2013, vol 62, no. 5, pp. 622–633. doi:10.1016/j.metabol.2012.11.004Uygun A., Kadayifci A., Demirci H. et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med, 2015, vol. 26, no. 1, pp. 37–41. doi:10.1016/j.ejim.2014.11.007Uygun A., Kadayifci A., Demirci H. et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med, 2015, vol. 26, no. 1, pp. 37–41. doi:10.1016/j.ejim.2014.11.007van Raalte D. H., van der Zijl N. J., Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr Opin Clin Nutr Metab Care, 2010, vol. 13, no. 4, pp.:478–485. doi:10.1097/MCO.0b013e32833aa1efvan Raalte D. H., van der Zijl N. J., Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr Opin Clin Nutr Metab Care, 2010, vol. 13, no. 4, pp.:478–485. doi:10.1097/MCO.0b013e32833aa1efVanWagner L.B., Wilcox J. E., Colangelo L. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology, 2015, no. 62, pp. 773–83. doi:10.1002/hep.27869VanWagner L.B., Wilcox J. E., Colangelo L. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology, 2015, no. 62, pp. 773–83. doi:10.1002/hep.27869Vege S.S., Gardner T. B., Chari ST. et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include “moderately severe acute pancreatitis.” Am J Gastroenterol, 2009, no. 104, pp. 710–715. doi:10.1038/ajg.2008.77Vege S.S., Gardner T. B., Chari ST. et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include “moderately severe acute pancreatitis.” Am J Gastroenterol, 2009, no. 104, pp. 710–715. doi:10.1038/ajg.2008.77Virtue S., Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol, 2008, vol. 6, no. 9, e237. doi:10.1371/journal.pbio.0060237Virtue S., Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol, 2008, vol. 6, no. 9, e237. doi:10.1371/journal.pbio.0060237Weng S., Zhou J., Chen X. et al. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore), 2018, vol. 97, no. 26, e11293. doi:10.1097/MD.0000000000011293Weng S., Zhou J., Chen X. et al. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore), 2018, vol. 97, no. 26, e11293. doi:10.1097/MD.0000000000011293Whitcomb D. C. Clinical practice. Acute pancreatitis. N Engl J Med, 2006, no. 354, pp. 2142–2150. doi:10.1056/NEJMcp054958Whitcomb D. C. Clinical practice. Acute pancreatitis. N Engl J Med, 2006, no. 354, pp. 2142–2150. doi:10.1056/NEJMcp054958Wong V.W., Wong G. L., Yeung J. C. et al. Longterm clinical outcomes aft er fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology, 2016, no. 63, pp. 754–63. doi:10.1002/hep.28253Wong V.W., Wong G. L., Yeung J. C. et al. Longterm clinical outcomes aft er fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology, 2016, no. 63, pp. 754–63. doi:10.1002/hep.28253Wu R., Hou F., Wang X. et al. Nonalcoholic fatty liver disease and coronary artery calcification in a northern chinese population: a cross sectional study. Sci Rep, 2017, no. 7, pp. 9933–4. doi:10.1038/s41598–017–09851–5Wu R., Hou F., Wang X. et al. Nonalcoholic fatty liver disease and coronary artery calcification in a northern chinese population: a cross sectional study. Sci Rep, 2017, no. 7, pp. 9933–4. doi:10.1038/s41598–017–09851–5Younossi Z., Anstee Q. M., Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, no. 15, pp. 11–20. doi:10.1038/nrgastro.2017.109Younossi Z., Anstee Q. M., Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, no. 15, pp. 11–20. doi:10.1038/nrgastro.2017.109Yu T., Wang C. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J Diabetes Investig, 2017, no. 8, pp. 735–747. doi:10.1111/jdi.12665Yu T., Wang C. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J Diabetes Investig, 2017, no. 8, pp. 735–747. doi:10.1111/jdi.12665Zhou J., Li M. L., Zhang D. et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology, 2016, vol. 16, no. 4, pp. 578–583. doi:10.1016/j.pan.2016.03.008Zhou J., Li M. L., Zhang D. et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology, 2016, vol. 16, no. 4, pp. 578–583. doi:10.1016/j.pan.2016.03.008Zhou Y.Y., Zhou X. D., Wu S. et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and metaanalysis. Hepatology Communications, 2018, vol. 2, no. 4, pp. 376–392. doi:10.1002/hep4.1155Zhou Y.Y., Zhou X. D., Wu S. et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and metaanalysis. Hepatology Communications, 2018, vol. 2, no. 4, pp. 376–392. doi:10.1002/hep4.1155Zsóri G., Illés D., Ivány E. et al. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord, 2019, vol. 17, no. 5, pp. 289–295. doi:10.1089/met.2018.0086Zsóri G., Illés D., Ivány E. et al. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord, 2019, vol. 17, no. 5, pp. 289–295. doi:10.1089/met.2018.0086Zyromski N.J., White P. B. Pancreatic cancer in obesity: epidemiology, clinical observations, and basic mechanisms. Anticancer Agents Med Chem, 2011, vol. 11, no. 5, pp. 470–478. doi:10.2174/187152011795677445Zyromski N.J., White P. B. Pancreatic cancer in obesity: epidemiology, clinical observations, and basic mechanisms. Anticancer Agents Med Chem, 2011, vol. 11, no. 5, pp. 470–478. doi:10.2174/187152011795677445

The authors declare that there are no conflicts of interest present.